Schrödinger reported second quarter 2026 financial results with total revenue of $58.9 million, an 8% increase year-over-year. Annual contract value (ACV) reached $29.6 million, reflecting 27% growth, while software revenue declined 10% to $32.5 million due to a transition to hosted licensing. Drug discovery revenue rose to $23.0 million, driven by a $10 million milestone from the Ajax Therapeutics acquisition. The company reported net income of $6.0 million compared to a net loss of $43.2 million in the prior year period, aided by a $45.9 million gain on equity investments linked to Eli Lilly’s acquisition of Ajax Therapeutics. Operating expenses decreased 6% to $74.0 million. The company raised its full-year drug discovery revenue guidance to $65–$75 million and expects ACV growth of 10–15%. Schrödinger operates in the biotechnology software industry, providing computational platforms for molecular discovery and drug development.

Schrödinger, Inc. received approximately $57 million in cash following Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc., a company co-founded by the registrant. The Company is also eligible for additional cash payments contingent upon Ajax achieving specific clinical and regulatory milestones. Schrödinger, Inc. is a software-based drug discovery company.

At its 2026 Annual Meeting of Stockholders on June 22, 2026, Schrödinger, Inc. stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of common shares available for issuance by 3,000,000. Stockholders also elected Richard A. Friesner, Rosana Kapeller-Libermann, and Gary Sender as Class III directors for three-year terms, approved the advisory vote on executive compensation, and ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company provides a physics-based software platform for drug discovery and provides computational chemistry and molecular biology software.

Schrodinger, Inc. announced the terms of a separation agreement with Mannix Aklian, the former Chief Commercial Officer, Global Head of Software Sales and Marketing. The agreement includes salary continuation for nine months, COBRA premiums for 12 months, and a prorated annual bonus of $88,096.